About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

CHICAGO, October 15, 2024--(BUSINESS WIRE)--MAIA Biotechnology ... telomere-targeting THIO prodrugs has been accepted for poster presentation during the upcoming 36 th EORTC-NCI-AACR Symposium ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American ...

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American ... Updated results” was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual ...